Montelukast reduces grey matter abnormalities and functional deficits in a mouse model of inflammation-induced encephalopathy of prematurity

Montelukast reduces grey matter abnormalities and functional deficits in a mouse model of inflammation-induced encephalopathy of prematurity

Abstract Encephalopathy of prematurity (EoP) affects approximately 30% of infants born < 32 weeks gestation and is highly associated with inflammation in the foetus. Here we evaluated the efficacy of montelukast, a cysteinyl leukotriene receptor antagonist widely used to treat asthma in children,...

Full description

Bibliographic Details
Main Authors: Abi G. Yates, Elena Kislitsyna, Carla Alfonso Martin, Jiaying Zhang, Amy L. Sewell, Ane Goikolea-Vives, Valerie Cai, Lama F. Alkhader, Aleksander Skaland, Basil Hammond, Ralica Dimitrova, Dafnis Batalle, Cathy Fernandes, A. David Edwards, Pierre Gressens, Claire Thornton, Helen B. Stolp
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Journal of Neuroinflammation
Subjects:
Inflammation
Preterm brain injury
Montelukast
Parvalbumin
Diffusion MRI
Online Access:https://doi.org/10.1186/s12974-022-02625-5

Internet

https://doi.org/10.1186/s12974-022-02625-5

Similar Items